
Pharmacovigilance Safety Monitoring in Clinical Trials
Author(s) -
Supriya Nikam,
Anjali Jambhulkar,
Kalyani Kayande,
Abhilasha Ghule,
Akash Inde
Publication year - 2021
Publication title -
international journal of pharmaceutical sciences review and research
Language(s) - English
Resource type - Journals
ISSN - 0976-044X
DOI - 10.47583/ijpsrr.2021.v70i01.002
Subject(s) - pharmacovigilance , safety monitoring , medicine , clinical trial , patient safety , drug development , risk analysis (engineering) , process safety , adverse effect , intensive care medicine , drug , pharmacology , business , health care , work in process , bioinformatics , pathology , marketing , economics , biology , economic growth
Pharmacovigilance is that the science and activities associated with the gathering, detection and assessment of adverse event data.Major purpose of pharmacovigilance is to gauge the benefit- risk profile of drug for better efficacy and safety to be used in patients.Pharmacovigilance plays a major role in rationale use of drug which provides the information about the adverse drug reactions whichseen in patients. In terms of volume Indian Pharma industry is third largest in world and in terms of value id thirteen largest in world.India is also known as a hub for clinical research and drug development. There is a requirement of a global and standardizedpharmacovigilance system in India for better safety assessment in India. In drug development process the only priority of clinical trialsis to make sure patient safety during and after the trials. A critical component throughout the drug development life-cycle ismonitoring patient safety. Patient must be treated consistent with the requirements and illness of patient therefore the utmost valueis given to monitoring of patient safety in the least levels of drug development. Such monitoring may be a dynamic process so toapproach safety monitoring. To ensure a systematic approach to safety monitoring pharmaceutical sponsor must work proactivelyand collaboratively with all stakeholders. We have to focus upon all the aspects of drug safety in clinical trials including basics of drugsafety, regulatory aspects of drug safety, patient suitability for safety in trials, post marketing safety and causality risk assessment of the drug products.